Peroxisome proliferator-activated receptor-γ agonists in atherosclerosis: Current evidence and future directions

Current Opinion in Lipidology

Volumn 14, Issue 6, 2003, Pages 567-573

  Roberts, Aled W ^a   Thomas, Andrew ^b   Rees, Alan ^a   Evans, Marc ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Atherosclerosis; Pioglitazone; PPAR ; Rosiglitazone; Thazolidinediones; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; C REACTIVE PROTEIN; ENDOTHELIN 1; LIPOPROTEIN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ALBUMINURIA; ARTERIOSCLEROSIS; BLOOD; BLOOD PRESSURE; CAROTID ARTERY; DRUG EFFECT; DRUG POTENTIATION; HISTOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RESTENOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ALBUMINURIA; ARTERIOSCLEROSIS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CAROTID ARTERIES; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPOPROTEINS; MATRIX METALLOPROTEINASES; METFORMIN; MUSCLE, SMOOTH, VASCULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 1542757734     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200312000-00004     Document Type: Review

References (71)

1. Kannnel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 1979; 2:120-126.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
3. UKPDS Group. UK Prospective Diabetes Study 6: Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990; 13:1-11.
4. Lillioja S, Mott DM, Spraul M, et al. Insulin Resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993; 329:1988-1992.
5. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 2002; 25:1135-1141. This study related insulin resistance to increased risk of cardiovascular disease in a large cohort of patients studied prospectively. The paper also discusses some possible mechanisms by which hyperinsulinaemia may result in atherosclerosis.
6. Haffner S, D'Agostini R, Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 1999; 22:562-568.
7. UK Prospective Study Group. Effects of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
8. Kirpichnikov D, McFarlane S, Sowers J. Metformin: an update. Ann Intern Med 2002; 137:25-31. This is an excellent review of metformin, in particular in relation to possible beneficial effects on cardiovascular risk.
9. Debril M-B, Renaud J-P, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor y. J Mol Med 2001; 79:30-47.
10. Berger J, Moller D. The mechanism of action of PPARs. Annu Rev Med 2002; 53:409-435. This is a comprehensive review of PPAR mechanisms of action including discussion of some of the pleiotropic effects of PPARγ activation.
11. Carey D, Cowin G, Galloway G, et al. Rosiglitazone increases insulin sensitivity and reduces factors associated with insulin resistance in type 2 diabetics. Diabetes Res Clin Pract 2000; 50 (Suppl 2):S64.
12. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
13. Iiyama K, Hajra L, Iiyama M, et al. Patterns of VCAM-1 and ICAM-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85:199-207.
14. Pasceri V, Wu H, Willersen J, Yeh E. Modular of vascular inflammation in vitro and in vivo by peroxisome proliferator activated receptor-γ activators. Circulation 2001; 101:235-238.
15. Wang N, Verna L, Chen N-G, Chen J, et al. Constitutive activation of peroxisome proliferator-activated receptor-γ suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 2002; 277:34176-34181.
16. Gu L, Okada Y, Clinton SK, Gerard C, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2:275-281.
17. Ishibashi M, Egashira K, Hiasa K, Inoue S. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40:687-693. Much research is focussed at this early stage of atherogenesis; PPARγ activation appears to be effective in preventing monocyte adhesion to the vascular endothelium which is expressing adhesion molecules, thus inhibiting atherogenesis at an early stage.
18. Han K-H, Chang MK, Boullier A, et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptorγ. J Clin Invest 2000; 106:793-802.
19. Hansson G, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135:169-175.
20. Van der Wal AC, Das PK, Bentz, van de Berg D, et al. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61:166-170.
21. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis: CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996; 149:359-366.
22. Jonasson L, Holm J, Skalli O, et al. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985; 76:125-131.
23. -/- mice. Am J Pathol 2000; 157:1819-1824.
24. Kwak B, Myit S, Mulhaupt F, et al. PPARγ but not PPARα ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells. Circ Res 2002; 90:356-362. This paper associates PPARγ activation with suppressed MHC-II, and a postulated reduction in T-cell activity at the site of atherogenesis. Inhibition of T-cell activation may have synergistic effects with the observed antiinflammatory effects of PPARγ activation on monocytes.
25. Jiang C, Ting A, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
26. Ricote M, Li C, Wilson T, et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
27. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95:7614-7619.
28. Tontonoz P, Nagy L, Alvarez JGA, et al. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252.
29. Chawla A, Boisvert WA, Lee C-H, et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7:161-171.
30. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor-γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274:9116-9121.
31. Law R, Goetze S, Xi X-P, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101:1311-1318.
32. Law R, Meehan W, Xi X-P. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98:1897-1905.
33. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
34. Haffner SM, Greenberg A, Weston WM, et al. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-684.
35. Marx N, Froehlich J, Siam L. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease, arteriosclerosis, thrombosis and vascular biology 2003; 23:283-288.
36. Marx N, Schönbeck U, Lazar MA, et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83:1097-1103.
37. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Path 1998; 153:17-23.
38. Choi SH, Choi DH, Ko YK, et al. Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Diabetes 2003; 52 (Suppl 1):A19 [oral presentation]. Basic science theory was tested in a clinical study, which related the possible anti-inflammatory effects of rosiglitazone in the endothelium to real clinical benefits observed as reductions in coronary stent restenosis rates.
39. Sobel BE, Frye R, Detre KM, et al. BARI-2D Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003; 107:635-642.
40. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565. This provides further evidence in support of the role of inflammation in atherosclerosis.
41. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26:386-391.
42. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96:1432-1437.
43. Wofford JL, Kahl FR, Howard GR, et al. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 1991; 11:1786-1794.
44. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22.
45. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151:478-487.
46. Koshiyama H, Shimono D, Kuwamuru N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86:3452-3456.
47. Ross R. The pathogenesis of atherosclerosis:a perspective for the 1990s. Nature 1993; 362:801-809.
48. Ross R. Mechanisms of disease: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
49. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000; 7:159-163.
50. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitising agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomised clinical trial. Metabolism 2003; 52:173-180.
51. Natali A, Baldeweg S, Toschi E, et al. Rosiglitazone directly improves endothelial function in type 2 diabetic patients. Diabetes 2002 51 (Suppl 2); P-573:A142.
52. Paradisi G, Steinberg HO, Shepard MK, et al. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:576-580.
53. Bertani T, Gambara V, Remuzzi G. Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. Diabetologia 1996; 39:1625-1628.
54. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996; 19:1243-1248.
55. Mietinnen H, Haffner SM, Lehto S, et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27:2033-2039.
56. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003; 17:7-12. Microalbuminuria is increasingly recognized as a marker of cardiovascular risk in type 2 diabetes. Reduction in microalbuminuria, as demonstrated here with rosiglitazone, is discussed as a result of the effects of the thiazolidinediones on blood pressure, vascular function and other mechanisms.
57. Diep QN, Mabrouk M EI, Cohn JS. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 2002; 105:2296-2302.
58. Sutton M St J, Rendell M, Dandona P. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25:2058-2064.
59. Miller RC, Pelton JT, Huggins JP. Endothelins: from receptors to medicine. Trends Pharmacol Sci 1993; 2:54-60.
60. Satoh H, Tsukamoto K, Hashimoto Y. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun 1999; 254:757-763.
61. Iglarz M, Touyz RM, Amiri F. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003; 23:45-51.
62. Juhan-Vague I, Roul C, Alessi MC, et al. Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients-Relationship with Plasma Insulin. Thrombosis and Haemostasis 1989; 61(3):370-373.
63. Thōgersen AM, Jansson J-H, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 93:2241-2247.
64. Kato K, Satoh H, Endo Y, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARγ in endothelial function. Biochem Biophys Res Commun 1999; 258:431-435.
65. Chu J, Abbasi F, Lamendola C, et al. Improvements in vascular and inflammatory markers in rosiglitazone treated insulin-resistant subjects are independent of changes in insulin sensitivity or glycaemic control. Diabetes 2003; 52 (Suppl 1):A76-A325.
66. Hoeg JM. Lipoproteins and atherogenesis. Endocrinol Metab Clin North Am 1998; 27:569-584.
67. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695-1702.
68. Assman G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAN experience): prospective cardiovascular Munster study. Am J Cardiol 1992; 85:37-45.
69. Robins SJ, Collins D, Wittes JT, et al. Relation of Gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomised controlled trial. JAMA 2001; 285:1585-1591.
70. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25:708-711.
71. Lee C, Edwards G, Maher L, et al. Favourable effects of Pioglitazone mono or combination therapy on the atherogenic index of plasma: a surrogate marker of LDL particle size. Diabetes 2003; 52 (Suppl 1):A160-A688.